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Abstract: This study aims to evaluate in vitro the release
properties and biological behavior of original compositions
of strontium (Sr)-loaded bone mineral cements. Strontium
was introduced into vaterite CaCO3-dicalcium phosphate
dihydrate cement via two routes: as SrCO3 in the solid
phase (SrS cements), and as SrCl2 dissolved in the liquid
phase (SrL cements), leading to different cement composi-
tions after setting. Complementary analytical techniques
implemented to thoroughly investigate the release/dissolu-
tion mechanism of Sr-loaded cements at pH 7.4 and 37!C
during 3 weeks revealed a sustained release of Sr and a
centripetal dissolution of the more soluble phase (vaterite)
limited by a diffusion process. In all cases, the initial burst of
the Ca and Sr release (highest for the SrL cements) that
occurred over 48 h did not have a significant effect on the
expression of bone markers (alkaline phosphatase, osteocal-
cin), the levels of which remained overexpressed after 15
days of culture with human osteoprogenitor (HOP) cells. At
the same time, proliferation of HOP cells was significantly
higher on SrS cements. Interestingly, this study shows that
we can optimize the sustained release of Sr2þ, the cement
biodegradation and biological activity by controlling the
route of introduction of strontium in the cement paste.
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INTRODUCTION
Trace elements, such as sodium, magnesium, strontium, and
fluoride, are naturally found in human bone.1,2 They have
attracted attention because previous studies have shown
that they have an impact on bone mineral characteristics
and on the biological activity of resorbable bone substi-
tutes.3–15 Research has particularly focused on the role
played by strontium on bone formation and remineraliza-
tion and it has led to therapies against bone degradation
and especially against osteoporosis.4,5,16 Strontium has been
tested in different forms: carbonate, chloride, lactate, and
ranelate.4,16
Strontium, already present in human plasma at concen-
trations of between 0.11 and 0.31 lmol#L$1, is a bone-seek-
ing element (more than 99% of strontium is located in the
bones).3 Previous studies have shown that, at a low dose,
strontium hinders osteoclast activity and favors the prolifer-
ation of osteoblast cells3,4,11; therefore, on the one hand it
acts synergistically against osseous resorption, while on the
other hand it acts by increasing the number of sites of osse-
ous formation. Other authors have reported the stimulating
action of strontium on osseous collagen formation.3,8–11
Nevertheless, it has been shown that at higher doses, stron-
tium can have deleterious effects on bone mineralization:
mineral density and calcium absorption are both reduced.3
High doses of strontium may also be one of the causes of
the development of osteomalacia.3,17 In addition, some
authors have reported the initial and prolonged microbial
inhibition of strontium-doped apatite coatings.18
In most cases, strontium (Sr) has been orally administered
in concentrations ranging from 0.1 to 767 mg Sr/kg/day.1,3
However, in the case of oral administration, it has been shown
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that even with high doses, less than 1 out of 10 Ca ions is
substituted by Sr in the newly formed bone.1 It seems that
the local release of Sr from the bone substitute, directly into
the osseous site, may be a solution for targeting a high turn-
over location while diminishing the administered strontium
dose. Therefore, strontium has recently been introduced
into hydroxyapatite-coatings, cements, dense or porous
ceramics, and granulates.12,13,15,18–25
Because of its higher atomic weight compared to calcium
and phosphate, strontium has also recently been proposed
and studied as an interesting contrast agent for increasing the
radio-opacity of calcium phosphate ceramics.21,26
Calcium carbonate-calcium phosphate mixed cements
have been presented as a promising resorbable and inject-
able material for bone reconstruction.27,28 The amount of
strontium introduced into calcium-phosphate bone cement
has to be optimized in order to provide both sufficient ra-
dio-opacity for the cement to be easily visualized and
detected during minimally invasive surgery procedures and
enough to favor bone formation without having deleterious
effects on bone mineralization. However, to the best of our
knowledge, no upper limit for the amount of strontium that
should be incorporated into a bony defect has yet been
defined.
In the present study, we investigated the introduction of
strontium into a calcium carbonate-calcium phosphate
cement through two different routes (Sr introduced as a
mineral salt either in the solid phase or dissolved in the li-
quid phase) and its in vitro effect on cement release proper-
ties and on human osteoprogenitor cell activities in contact
with these cements. Physico-chemical characterizations
were performed in order to determine the effects of stron-
tium and the way it is introduced into the self-setting paste
on hardened cement composition and properties. Finally,
in vitro assays were performed to evaluate the effect of
strontium-loaded cements on the proliferation and differen-
tiation of human osteoprogenitor cells isolated from bone
marrow stromal cells to emphasize the link between stron-
tium release and the activity of bone forming cells.
MATERIALS AND METHODS
Reactive powder synthesis
The solid phase of the reference cement (without strontium)
was composed of dicalcium phosphate dihydrate (DCPD)
and CaCO3-vaterite (V), which were synthesized by precipi-
tation at ambient temperature as previously described in
detail.27 Commercial strontium salts with different solubi-
lities were purchased and used without further purification:
SrCO3 (Alfa Aesar
VR ) was introduced in the solid phase and
SrCl2.6H2O (Normapur
VR ) in the liquid phase.
Paste preparation
As previously described in detail, the reference cement paste
was manually prepared by mixing equal weight of vaterite and
DCPD (1:1) with deionized water as the liquid phase.27 The
liquid to solid ratio (L/S) was equal to 0.5 (w/w).
Strontium was introduced into the cement either in the
solid phase or in the liquid phase by means of strontium
salts with different solubilities. Considering the properties
of different strontium salts (chloride, nitrate, carbonate,
etc.), commercially available SrCO3 and SrCl2.6H2O were
chosen to introduce Sr in the cement via the solid or via the
liquid phase, respectively. In the case of SrCO3, carbonate
ions were already present in the reference cement; conse-
quently no other type of counter-ions would therefore be
introduced in the cement. In addition, SrCO3 has a solubility
close to that of vaterite CaCO3 which is already present in
the cement; consequently SrCO3 should be resorbable.
SrCl2.6H2O salt was selected to introduce Sr in the cement
via the liquid phase because of its high solubility and of the
non-toxicity of counter-ions (Cl$).
Table I details the composition of the different cement
pastes: the reference cement (without strontium) is identi-
fied as ‘‘ref ’’, cements where SrCO3 was introduced in the
solid phase as ‘‘SrS’’ and cements where SrCl2 was dissolved
in the liquid phase as ‘‘SrL’’.
On the one hand, varying amounts of the less soluble
salt, strontium carbonate (SrCO3), were added to the solid
phase including the same weight ratio of vaterite and DCPD
(1:1) and thus led to various weight percentages (wt%) of
SrCO3 in the solid phase (5, 10, 15, or 20 wt%) and conse-
quently to various wt% of Sr in the paste (2, 4, 6, or 8%,
respectively). These cements were prepared with the same
L/S ratio (0.5) as the reference paste (Table I).
On the other hand, varying amounts of the more soluble
salt, i.e., strontium chloride (SrCl2.6H2O), were dissolved in
deionized water resulting in solutions with different concen-
trations in Sr2þ ions and viscosities. The reference solid
TABLE I. Composition of the Pastes of the Different Sr-Loaded Cements
Solid Phase Liquid Phase Paste
DCPD (g) Vaterite (g) SrCO3 (g) Deionized water (g) SrCl2.6H2O (g) Wt% of Sr
Ref 1 1 0 1 0 0%
SrS 0.95 0.95 0.1 1 0 2%
SrS 0.90 0.90 0.2 1 0 4%
SrS 0.85 0.85 0.3 1 0 6%
SrS 0.80 0.80 0.4 1 0 8%
SrL 1 1 0 0.82 0.18 2%
SrL 1 1 0 0.638 0.362 4%
SrL 1 1 0 0.581 0.419 4.7%
SrL 1 1 0 0.458 0.542 6%
phase (DCPD þ V; 1:1) was then mixed with the as-pre-
pared Sr solutions, leading to pastes that were prepared
with the same L/S ratio (0.5) as the reference paste, con-
taining various wt% of Sr (2, 4, 4.7, or 6 wt%) (Table I).
Note that because of the solubility of SrCl2.6H2O in water,
the maximum amount of Sr dissolved in the liquid phase
and consequently included in the paste via this route was
6 wt% (compared to 8 wt% for the SrS cements).
In all cases (reference or Sr-loaded cements), the paste
was then left to set in a sealed container at 37!C and in an
atmosphere saturated with water (%100% humidity). The
hardened and dried cements were analyzed after matura-
tion for four days at 37!C.
Powder and cement characterization
All of the synthesized and commercial powders and the ref-
erence and Sr-loaded hardened cements were characterized
by transmission Fourier transformed infrared (FTIR)
spectroscopy with KBr pellets (Nicolet 5700 spectrometer,
ThermoElectron), X-ray diffraction (XRD) (Inel CPS 120 dif-
fractometer) using a Co anticathode (k ¼ 1.78897 Å) and
scanning electron microscopy (SEM) (LEO 435 VP micro-
scope; silver plating of sample before observation).
A preliminary Rietveld refinement analysis was per-
formed on SrL cement XRD patterns. The MAUD program
was used to refine the lattice parameters.29 Space groups,
cell parameters, and atomic positions of the different
phases: vaterite and Sr-substituted hydroxyapatite, were
introduced as initial structural models.30,31 The Caglioti
function (half the width of the diffraction peaks as a func-
tion of 2y) was evaluated using a LaB6 powder (NIST-
660B). The peak shapes were fitted by using a pseudo-Voigt
function. The errors on the calculated unit cell parameters
were 6.10$3 Å for a and 3.10$3 Å for c.
In vitro release tests
Release tests. Release tests were performed under SINK
conditions on three types of set cement (reference, 8% SrS
and 4.7% SrL cements) in accordance with European Phar-
macopoeia specifications. A Dissolutest apparatus
(PharmatestVR ) containing six bowls equipped with rotating
paddles (rotating speed ¼ 100 rpm) was used. Each cylinder
of hardened cement (height ¼ 20 mm, diameter ¼ 10.6 mm,
average weight: 1.44 6 0.05 g (ref); 1.70 6 0.06 g (SrS);
2.4 6 0.1 g (SrL)) was immersed for three weeks in 1 L of a
buffer solution composed of 0.1M tris(hydroxyme´thyl)amino-
methane NH2C(CH2OH)3 at physiological pH 7.4. The bowls
were sealed and kept at a temperature of 37!C.
Samples of 10 mL of the working solution (buffer solu-
tion in which the cement had begun to dissolve) were
removed at different times and replaced by the same vo-
lume of fresh buffer solution to keep the volume of the
release medium constant throughout the experiment. The
dilution factors that followed from this adjustment were
considered in all calculations.
Even if no particles or very few particles were released
from the cements, the solutions removed were then filtered
using 0.2 lm cellulose membrane filters to remove potential
particles that could dissolve during storage of the solution
before analysis and which could interfere during the analy-
sis. The filtrates were stored at þ4!C before analysis. This
experiment was performed in triplicate for each type of
cement tested.
Characterization of the working solution. Concentrations
of Ca and Sr in the working solution removed at different
times were determined using atomic absorption spectros-
copy (AAS) (PerkinElmer Flamme AAS, AAnalyst 400).
Standard solutions from 0 to 5 ppm (linearity range for
both Ca and Sr) were prepared using the same buffer solu-
tion as the one used for the release tests. Except for the
samples removed at the earliest times (lowest calcium and
strontium concentrations), the samples were diluted before
measurements with the same buffer solution to reach the
0–5 ppm range.
Characterization of cements after release test. After three
weeks in the buffer solution, the cements that had been
immersed were removed from the solution and dried in an
oven at 37!C. For each type of cement, two samples were
manually ground and replaced in their respective working
solution for an additional 24 h to determine the maximum
amounts of calcium and strontium that could possibly be
dissolved under these experimental conditions. The third
sample was characterized by the analytical techniques indi-
cated in the Powder and Cement Characterization section.
Raman micro-spectroscopy (Labram HR 800 Horiba Jobin
Yvon micro-spectrometer) and porosimetry analyses were
carried also out. The total porosity of the cements was
determined using a mercury intrusion porosimeter (Auto-
pore IV 9400 MicromeriticsVR Instruments Inc.) with a 5 cm3
solid penetrometer. Energy dispersive X-ray (EDX) elemental
mapping was performed using a scanning electron micro-
scope LEO 435 VP and an IMIX-PGT analyser (Princeton
Gamma Tech) equipped with a Ge detector.
In vitro cell culture study
Cell viability, proliferation, and differentiation were eval-
uated in vitro for the three types of cement in direct contact
with human osteoprogenitor cells: the reference cement, the
SrCO3-loaded cement (8% SrS), and the SrCl2-loaded cement
(4.7% SrL). Cement disks (1 cm diameter and 4 mm thick-
ness) were prepared and polished until smooth after the
cement had set to give an even surface. The cement disks
were then sterilized by c-ray irradiation (25 KGy) before
the cell culture assays.
Cell culture. Osteoprogenitor cells were isolated from
human bone marrow stromal cells (HBMSCs) according to
the method of Vilamitjana-Ame´de´e et al. with some modifi-
cations.32,33 Briefly, human bone marrow was obtained by
aspiration from the iliac crest of healthy donors (aged
20–50 years) undergoing hip prosthesis surgery. The cells
were separated into a single suspension by sequentially
passing the suspension through syringes fitted with 16, 18,
or 21 gauge needles. After centrifugation for 15 min at
800 g, the pellet was resuspended in Iscove Modified Dul-
becco’s Medium (IMDM, from Gibco, InVitrogen, Carlsbad,
CA) supplemented with 10% (v/v) foetal calf serum (FCS,
from Gibco) and 10$8 M dexamethasone (Sigma, St. Louis,
MO) in order to drive the cells to the osteogenic phenotype.
The cells were then placed into 75 cm2 cell culture
flasks (Nalgene Nunc, Rochester, NY), at a density of 5 &
105 cells/cm2 and incubated in a humidified atmosphere of
95% air 5% CO2 at 37!C. Five days later, the medium was
removed, replaced twice with the complete medium supple-
mented with 10$8 M dexamethasone, and then every 3 days
replaced with IMDM containing 10% FCS (v/v). Subcultur-
ing was performed using 0.2% (w/v) trypsin and 5 mM
ethylenediaminetetraacetic acid (EDTA). Cell differentiation
was followed at different times during cell culture by mea-
suring alkaline phosphatase activity and osteocalcin synthe-
sis, as previously described.32
Cell viability and proliferation assays. Cell viability and
mortality were determined using a LIVE/DEAD viability/
cytotoxicity kit, according to the manufacturer’s protocol
(Molecular Probes). Cell proliferation assays, quantified by
MTT analysis were performed as described by Mosmann.34
All assays were performed using at least six replicates for
each condition tested. Cell proliferation on tissue culture
polystyrene (TCPS) in plastic culture dishes was used as the
positive control. In order to prevent cell attachment to the
plastic dishes, an agarose layer (2% (v/v) in 0.1 M phos-
phate buffered saline (PBS at pH 7.4) was deposited in the
wells, and the cement discs were placed on this layer and
incubated overnight at 37!C in IMDM. Thereafter, the discs
were seeded with 20 & 103 cells per cm2 in IMDM supple-
mented with 10% (v/v) FCS. The cultures were incubated
at 37!C in a humidified atmosphere. The culture medium
was renewed every 3 days. Cell growth was quantified after
1, 3, 9, and 15 days by measuring the metabolic activity
of the cells by the MTT assay. This assay is based on the
observation that a mitochondrial enzyme of viable cells has
the ability to metabolize a water-soluble tetrazolium dye
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
into an insoluble formazan salt. Briefly, 3 h after incubation
of the MTT solution at 37!C, the solution was removed, the
insoluble formazan crystals that had formed were dissolved
in dimethylsulphoxide and 100 lL was aspirated and
poured into another 96-well plate for absorbance measure-
ments at 540 nm. The intensity of the staining obtained was
directly proportional to the cell density (see AFNOR-NF EN
30993-5 and ISO 10993-5 standards). The cements were
removed from the milieu after 15 days of culture, dried at
37!C and then characterized by the analytical techniques
indicated in the Powder and Cement Characterization
section.
The culture media that were removed after incubation,
and one and nine days of cell culture were filtered through
cellulose membranes and the calcium and strontium concen-
trations were determined by absorption spectroscopy
(PerkinElmer SAA Flamme, AAnalyst 400, see the
Characterization of the Working Solution section).
Cell morphology and surface characterization. After 15
days of culture, SEM observations were carried out in order
to examine cell morphology on the culture discs. The samples
were fixed by 15 min immersion in a 2% (v/v) glutaralde-
hyde in 0.15 M cacodylate buffer (pH 7.3). The samples were
washed with 0.15 M cacodylate buffer for 10 min, then dehy-
drated by successive immersions in ethanol solutions (from
25 to 100%), and then finally dried by the CO2 critical point
technique and Au-sputtered before observation. SEM analyses
were carried out at 15 and 20 keV for 60 s using a Hitachi
(Tokyo, Japan) S-2500 scanning electron microscope.
Quantitative real time polymerase chain reaction
(Q-PCR). Total RNA was prepared from the cells using a Mach-
ery-Nagel Nucleospin RNA extract II kit, according to the manu-
facturer’s instructions. Adequacy of the RNA quality was
assessed photometrically and by agarose gel electrophoresis.
A 1 lg weight of RNA was used as a template for single-
strand cDNA synthesis using the Superscript system (Fisher
Scientific) in a final volume of 20 lL containing 20 mM
Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl2, 0.1 mg/mL
BSA, 10 mM DTT, 0.3 mM of each of dATP, dCTP, dGTP, and
dTTP, 0.5 lg oligo(dT)12-18 used as a primer and 50 U of
reverse transcriptase. After incubation at 42!C for 50 min,
the reaction was stopped at 70!C over a period of 15 min.
A 5 lL volume of cDNA diluted at a 1:80 ratio was
loaded in a 96-well plate and 20 lL of SYBR-Green Super-
mix (2X iQ: 50 mM KCl, 20 mM Tris-HCl (pH 8.4), 0.2 mM
of each dNTP, 25 U/lL iTaq DNA polymerase, 3 mM MgCl2,
SYBR-Green) stabilized in sterile water was added.
Primers of ubiquitary ribosomic protein PO (forward:
50ATGCCCAGGGAAGACAGGGC 30-reverse: 50CCATCAGCACC
ACAGCCTTC 30), alkaline phosphatase (ALP) (forward: 50AG
CCCTTCACTGCCATCCTGT 30-reverse: 50ATTCTCTCGTTCACCG
CCCAC 30) and osteocalcin (OC) (forward: ACCACATCG
GCTTTCAGGAGG 30-reverse: 50GGGCAAGGGCAAGGGGAAGAG30)
were used at the final concentration of 200 nM.
The data were analyzed with the iCycler iQ software and
compared using the DDCt method. Each Q-PCR was per-
formed in triplicate for PCR yield validation. The data were
normalized to PO mRNA expression for each condition. We
have chosen P0 as the reference or housekeeping gene that
encodes for a ribosomal protein and which is not influenced
by the experimental conditions. The results were thereafter
normalized to the expression of the corresponding gene,
expressed by the cells cultured on the plastic culture dishes
(that represent one as relative value). Statistical significance
was calculated by Student’s t-test.
RESULTS
Sr-loaded cement characterization
All compositions of the Sr-loaded pastes that were tested
(Table I) led to hardened cements. The set reference cement
was composed of vaterite and nanocrystalline apatite which
was shown to be carbonated in a previous paper.27 X-ray
diffraction analysis [Figure 1(a)] of the set cements showed
that when SrCO3 was included in the solid phase it
remained in the final cement, thus the composition was
comprised of carbonated apatite, vaterite, and strontianite
(SrCO3). The relative intensity of the diffraction peaks of
strontianite clearly increased as the initial load of SrCO3
increased indicating that this compound did not have a sig-
nificant part in the setting reaction. When strontium chlo-
ride was introduced into the paste via the liquid phase, no
additional phase was detected compared to the reference
cement [Figure 1(b)]. The preliminary Rietveld refinement
analysis of cement XRD diagrams enabled the determination
of apatite cell parameters as a function of Sr-loading in the
liquid phase and thus in the cement paste; the evolution of
these parameters can be observed in Figure 2 and com-
pared with the Vegard’s law, as described by Leroux et al.,
for partly substituted apatite Ca10-xSrx(PO4)6(OH)2.
35 Con-
sidering the study of Leroux et al., we can see that the a
parameter is higher than expected and that the c parameter
has a lower increase than expected. We can also note that
the increase in the c lattice parameter of the apatite formed
after setting is visually confirmed by the shift of the 002
line of apatite at about 2y ¼ 30–31! toward lower 2y values
as Sr introduced in the liquid phase increased [see Figure
1(b)]. The 00l lines of apatites are rather narrow and the
variation of the c parameter reported is more reliable and
significant than that for the a parameter.
The total porosity of the different Sr-loaded cements is
reported in Table II. The introduction of strontium into the
cement formulation led to a decrease of about 10% of the
total porosity compared with the total porosity of the refer-
ence cement. Upon examining the pore size distribution
(Figure 3) for the different Sr-loaded cements that were
prepared, it could be seen that when strontium wasFIGURE 1. X-ray diffraction patterns of the different Sr-loaded set
cements: (a) SrS cement; (b) SrL cement. V: CaCO3 – vaterite; A: nano-
crystalline apatite; S: SrCO3. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
FIGURE 2. Hydroxyapatite (Hap) cell parameters (a,c) as a function
of Sr load compared with (a) and (c) Vegard’s law (dotted lines)
according to Leroux et al.35
TABLE II. Total Porosity (%) of the Three Types of Cements
Before and After the In Vitro Release Test (3 Weeks)
Reference
Cement
8%
SrS Cement
4.7%
SrL Cement
Before release test 61 6 1 49 6 1 52 6 2
After release test 69 6 2 63 6 2 68 6 2
FIGURE 3. Pore size distribution of the three types of cement before
(a) and after (b) the in vitro release test.
introduced into the cement formulation, either in the solid
or liquid phase, the size of the bigger pores increased (for
example, from 4 to 26 lm for 8% SrS cement). It is impor-
tant to note that for all of the cements the nanosized pores
played a prominent role in the total porosity of the cement
(in the case of 8% SrS cement with a total porosity of 49%:
45% by the pores of an average size of 8 and 20 nm com-
pared to a contribution of 4% by pores of an average size
of 25 lm).
Strontium and calcium release in vitro
The concentrations of calcium and strontium ions released
from the different cements tested in the working solution
are plotted against time in Figure 4. Regarding calcium
release [Figure 4(a)], all of the cement types showed the
same trend: even though the SrL cements showed a higher
release rate, calcium was continuously released from the
cements, with a faster rate of release during the first 50 h
and slower afterward. The cumulated Ca concentration in
the working solution after 3 weeks reached 0.06 g/L for the
reference cement, 0.05 g/L for 8% SrS, and 0.08 g/L for the
4.7% SrL cement (values normalized per gram of cement
that was initially introduced into the working solution).
Regarding strontium release [Figure 4(b)], both
Sr-loaded cements showed different trends. Although it
contained less strontium, the amount of strontium released
from the SrL cement was higher than that from the SrS
cement during the first 50 h. Then the rate of strontium
release slowed down and reached similar or lower rates than
SrS cement after one week in solution. After 3 weeks of being
tested in the release solution, the cumulated Sr concentration
in solution reached 0.021 g/L for 8% SrS cement and 0.016
g/L for SrL cement (values normalized per gram of cement
that was initially introduced into the working solution).
In order to determine the mechanism of Sr release and
the dissolution of the cements, it was important to charac-
terize the cements after the in vitro tests in the presence or
absence of cells: X-ray diffraction analysis provided the
global composition of the cement, whereas Raman micro-
spectroscopy provided the local one.
Figure 5 presents the XRD diagrams of the three types of
cement blocks after the in vitro tests: (i) as removed from
the working solution after 3 weeks [Figure 5(a)]; (ii)
removed from the working solution after 3 weeks, manually
ground in a mortar, and replaced as powders in their respec-
tive working solutions for an additional 24 h [Figure 5(b)];
(iii) after 15 days of the cell culture test [Figure 5(c)]. By
comparing Figures 1 and 5, we can see that the composition
of the cement blocks was similar before (Figure 1) and after
the in vitro tests in both the absence and presence of cells
FIGURE 4. Concentrations of calcium and strontium released from the
different cements tested in the working solution as a function of time:
(a) Ca released from: (i) reference cement; (ii) SrCO3-loaded cement
(SrS) including 8 wt% Sr in the paste; (iii) SrL including 4.7 wt% Sr in
the paste (b) Sr released from: (i) reference cement; (ii) SrCO3-loaded
cement (SrS) including 8 wt% Sr in the paste; (iii) SrL including
4.7 wt% Sr in the paste. Data shown are mean 6 SD (n ¼ 3).
FIGURE 5. X-ray diffraction patterns of the three types of cement: (a)
after 3 weeks of the in vitro release test; (b) after the in vitro release
test for 3 weeks as a cement block and one more day as ground pow-
der; (c) after 15 days of the in vitro cell culture.
[Figure 5(a,c), respectively]: vaterite remained in the three
types of cements either after three weeks in buffered solu-
tion or after two weeks in contact with culture medium and
cells. However, a significant difference can be clearly
observed for the XRD patterns of the cement powders
replaced in the working solution for an additional 24 h [Fig-
ure 5(b)]: the diffraction peaks characteristic of vaterite are
no longer visible on the XRD pattern of the SrS cement and
they are of a very low intensity for the reference and SrL
cements. This indicates that the vaterite, which remained in
the cement blocks after 3 weeks, dissolved within 24 h when
the blocks were ground into powders. The resulting SrL
cement consisted of a poorly crystallized apatite showing
broader and less well resolved peaks than SrS or the refer-
ence cement. In the case of the SrS cement, it can be noted
that nanocrystalline apatite co-existed with the well-crystal-
lized SrCO3, which remained in the cement after the release
test regardless of the form of the cement (block or powder).
This result indicated that strontianite (SrCO3) was stable in
the Tris buffer solution at pH 7.4 and 37!C. However, in
order to further investigate the composition of these cements
after the 3-week release test, we performed elemental map-
ping by EDX and Raman micro-spectroscopy analyses on a
cross-section of the cement cylinders.
Elemental mapping of the three types of cement was per-
formed for calcium, phosphorus, and strontium (Figure 6). In
particular, the phosphorus maps revealed heterogeneity in the
composition with a brighter peripheral layer indicating a rela-
tively higher concentration of phosphorus than in the center
of the cement. However, this P-rich peripheral layer was less
marked for the SrL cement. Upon examination of the stron-
tium maps, it could be seen that this element was homogene-
ously distributed within the SrL cement, supporting the
hypothesis of the incorporation of Sr in the apatite lattice,
whereas for the SrS cement some brighter spots indicated the
presence of SrCO3 agglomerates that were not homogeneously
distributed. In addition a brighter peripheral layer can be dis-
tinguished for the SrL cement indicating a relatively higher
concentration in strontium than in the center of the cement
probably due to the preferential dissolution of vaterite in this
zone thus mainly consisting of strontium-substituted apatite.
Figure 7 shows the spectra of the SrS cement after 3 weeks
of in vitro release test compared with spectra of the reference
compounds (vaterite, SrCO3, and the carbonated apatite analo-
gous to bone mineral). The spectrum of the edge of the
cement cylinder mainly shows the characteristic band of the
phosphate groups in carbonated apatite (960 cm$1); a low in-
tensity band at 1070 cm$1 indicating the presence of SrCO3
could also be distinguished. Note that this band was superim-
posed on the band of very low intensity at 1070 cm$1,
characteristic of phosphate groups in carbonated apatite. This
spectrum was completely different from the one obtained
when the center of the cement was analyzed, where intense
bands characteristic of carbonate groups in vaterite
(1075–1090 cm$1) and SrCO3 (1070 cm
$1) were seen, along
with a less intense band characteristic of phosphate groups in
carbonated apatite. This Raman spectroscopy data confirmed
the EDX spectroscopic data (Figure 6).
Upon comparing the total porosity of the cements before
and after the release test (Table II), it can be seen that it
was significantly higher after the in vitro test: this increase
was more important for the Sr-loaded cements.
Examination of the pore size distribution after the in vitro
release test suggested the formation of a secondary porosity
during cement degradation in vitro [Figure 3(b)]. The pore
size distribution around 10 nm, which was bimodal before the
test for the reference and SrS cements, became monomodal
and broader toward the higher pore sizes; pores of about
100 nm were created. In addition, after the release test, the
SrL cements presented a secondary pore size distribution
(around 8 nm) of smaller pore sizes than before the test. A
broadening of the pore size distribution toward higher pore
sizes was noted for the SrS and SrL cements. This result could
have been due to degradation of the cements, and particularly
to the dissolution of vaterite CaCO3 and SrCO3.
In vitro cell culture study
Results were obtained from three separate experiments that
used human osteoprogenitor cell cultures arising from three
different donors of bone marrow. Figure 8 shows that the
cells seeded on Sr-loaded cements exhibited the same pro-
file of proliferation from day 1 to day 9 of culture as for the
reference cement. However, the rate of proliferation
remained significantly lower on these materials than on the
plastic culture dishes, especially at day 9 and day 15. After
15 days of culture, it was noted that the human osteoproge-
nitor cells showed a more significant proliferation on SrS
cement than on either the reference or the SrL cements.
Live/dead assays performed on the three types of
cements [Figure 9(d–f)] mainly revealed living cells on these
three surfaces. This analysis was corroborated by a SEM ex-
amination [Figure 9(a–c)], which showed cells that were
well spread out with numerous filopodia, regardless of the
substrate (reference, SrL, or SrS cements).
Q-PCR was performed to quantify the mRNA levels of the
early bone-specific marker (alkaline phosphatase) and the later
bone-specific marker (osteocalcin) after 15 days of culturing
the human osteoprogenitor cells on the three cement types
(reference, SrL and SrS) and on the plastic culture dishes as
control (Figure 10). The expression of ALP mRNA levels in
cells cultured on these three cements did not differ, regardless
of whether the cement was loaded with strontium or not. The
same result was obtained for the late osteoblastic marker
osteocalcin, which was not significantly regulated by the pres-
ence of strontium within the cements. However, the expression
of these two bone markers was overexpressed in cells cultured
on the three types of cements in comparison with the control
surfaces (plastic culture dishes), regardless of the presence of
strontium within the cements (Figure 10).
The concentrations of strontium and calcium released into
the culture medium after the overnight incubation of the
cements, after 1 and 9 days of cell culture, are presented in
Figure 11. A burst of release of strontium and calcium
occurred during incubation and on the first day of cell culture
for the 4.7% SrL cement, whereas their release was moderate
at 9 days of cell culture. The calcium release rate for 8% SrS
cement was quite similar to that of the reference cement
[Figure 11(a)]. The calcium and strontium release rates for
the 8% SrS cement were very low compared with those of
the 4.7% SrL cement, indicating a different bioavailability of
strontium and cement biodegradation properties depending
on the Sr-loading route chosen for the cement.
DISCUSSION
Sr-loaded cement compositions and properties
Several authors have investigated various routes for intro-
ducing strontium into apatite or brushite bone cements
and a commercial cement formulation includes strontium
carbonate.8,23,26,36–39 In all cases, strontium was introduced
in the solid phase. In the present study, we investigated the
introduction of strontium in solid and liquid phases and the
feasibility of both types of self-setting pastes was demon-
strated. Interestingly, the two different routes used to intro-
duce strontium into the cement led to two different compo-
sitions of cements: when SrCO3 was included in the solid
phase it remained in the final cement composition, whereas
when SrCl2 was dissolved in the liquid phase Sr
2þ ions
were readily available in the paste and could be incorpo-
rated into the apatite phase during the setting reaction by
substituting Ca2þ ions and consequently no additional phase
FIGURE 6. EDX elemental mapping (Ca, P, and Sr) of the three types of cement after three weeks of the release test. (I) Preparation of the
sample; (II) Ca, P and Sr elemental maps (magnification: &25; scale bar ¼ 400 lm; brighter points: higher concentration of the element). [Color
figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
was detected compared with the reference cement. Varia-
tions in a and c parameters of the apatite lattice were also
reported by Wang et al. as a function of the Sr/(CaþSr)
molar ratio when two routes of introduction of strontium in
the solid phase of amorphous calcium phosphate and DCPD
cement were investigated.39 The variation they reported for
the c parameter was higher (higher slope) than shown in
Figure 2 of the present study and was thus closer to that
reported by Leroux et al.35 The lower increase of c parame-
ter observed in the present study (Figure 2) could be due
to the concomitant substitution by strontium and chloride
(from SrCl2 salt dissolved in the liquid phase) in the apatite.
Indeed the effect of Sr on the crystallographic parameters of
apatite is rather large, especially on the c dimension,
whereas chlorine incorporation would have an opposite
effect on this dimension. In addition the 00l lines are rather
narrow due to elongated shape of the apatite crystals and
the variation reported is significant. These simple considera-
tions support the data obtained by our preliminary Riet-
veldt refinement analysis, considering also that the atomic
diffusion coefficient of Sr is much larger than that of Ca and
that even small amounts of Sr incorporation are quite
observable on XRD data as shown by several authors.11,39,41
However, it is important to note that in the present study,
the possibility of having concomitant substitution of calcium
by strontium and hydroxide by chloride, the coexistence of
various degrees of substitution into the apatite formed in
the SrL cement and its low crystallinity did not allow us to
obtain reliable quantitative information on the amount of
strontium incorporated in the apatite lattice. Considering
the work of O’Donnell et al. Raman spectroscopy can also
be useful to identify and quantify Sr substitution in
hydroxyapatite: the position of the m1PO4 band in hydroxy-
apatite (961 cm$1) decreased linearly for Sr-substituted
hydroxyapatites and the full width at half maximum of this
band can well correlated and increased linearly with
increasing crystallite size calculated by XRD analysis.40
These various cement compositions should lead to dif-
ferent behaviors of the cement in solution considering the
solubility of hydroxyapatite and of Sr-substituted hydroxy-
apatite. Indeed, the different crystallization and dissolution
properties of such apatites should determine the setting of
the cement (formation of apatite) and its biodegradation
and release properties. Christoffersen et al. reported the
inhibitory role of strontium on the rates of dissolution and
crystal growth of hydroxyapatite and 10% Sr-containing
hydroxyapatite; the latter was less affected than the former.41
Our results showed that partially substituted Sr-
hydroxyapatite was formed in SrL cements and that early
high rates of released calcium and strontium were detected
when the SrL cement was tested in vitro in both the presence
and absence of osteoprogenitor cells, whereas the SrS cement,
which was mainly composed of hydroxyapatite, showed a rel-
atively moderate release of ions. It is now interesting to dis-
cuss the release and dissolution properties of these cements.
Release and dissolution properties of strontium-loaded
cements
Several studies reported associations between calcium phos-
phate bone cements and drugs (antibiotics, bisphospho-
nates, and growth factors, for example) as in situ drug
release systems.42–46 However, very few studies investigated
strontium release from Sr-loaded cements.13,20 Alkhraisat
et al. investigated strontium release at 37!C in pure water
in dynamic conditions (water refreshed daily) for brushite
cements prepared with a solid phase including strontium-
substituted tricalcium phosphate.13
In the present work, we studied strontium release in a
buffered solution at pH 7.4 and 37!C over a period of
3 weeks. For both types of Sr-loaded cements, we observed
a sustained release of strontium for 3 weeks in both the
presence and absence of osteoprogenitor cells, including an
initial burst of release of Ca and Sr during the first 48 h
(Figures 4 and 11). After an initial period (24 h for the SrS
cement), the ratio of the Ca/Sr released then stabilized at
around 2.5 and remained constant throughout the rest of
the experiment. Note that the Ca/Sr ratio in the cement
paste was 2.1 and that the Ca/Sr ratio released was there-
fore higher. We can hypothesize that the CaCO3-vaterite,
which remained in the cement after the setting reaction
(Figure 1), and which is the more soluble phase, dissolved
first, explaining the high Ca/Sr ratio during the first couple
of days. Then, SrCO3 also began to dissolve, which explains
the decrease in the Ca/Sr ratio.
FIGURE 7. Raman spectra of the reference compounds and of two
zones of the 8% SrS cement after three weeks of the in vitro release
test.
FIGURE 8. Cell proliferation of human osteoprogenitor cells cultured
on the three cements for 15 days, quantified by MTT assays.
Data shown are mean 6 SD of triplicate experiments for each series
(* p ( 0.05).
The EDX elemental mapping revealed a relative increase
in phosphorus in the peripheral layer of all the cement
blocks, which confirms the hypothesis of the early dissolu-
tion of vaterite CaCO3 and consequently a relative
enrichment of the less soluble apatite in the peripheral layer
(Figure 6). This less soluble peripheral layer could consti-
tute a barrier that would slow down the dissolution of
vaterite from the core of the cement. However, this effect
could be partially compensated for by the formation of a
secondary porosity that could facilitate the diffusion pro-
cess. The Raman micro-spectroscopy analysis performed on
two regions of the SrS cement cylinder (edge and center,
Figure 6) after the release test confirmed the dissolution of
vaterite on the edge, suggesting that the vaterite dissolution
process was limited by diffusion during the in vitro test. In
addition, the centripetal dissolution of vaterite was confirmed
FIGURE 9. SEM micrographs of cement surfaces after 15 days of culturing human osteoprogenitor cells: (a) reference, (b) SrL and (c) SrS
cements. Live/dead assays were performed after 15 days of cell cultures: (d) reference, (e) SrL and (f) SrS cements. [Color figure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
by comparing the results of the X-ray diffraction analysis on
blocks and powders (ground cement blocks) removed after
the in vitro release tests [Figure 5(a,b)]. As diffusion is a less
limiting process for cement dissolution when in the form of a
powder compared to a block, vaterite was almost completely
dissolved within 24 h when the ground cement was tested in
the release solution [Figure 5(b)].
In the case of 4.7% SrL cement, the release of calcium
and strontium was very high during incubation and the first
day of cell culture (Figure 11), in correlation with
the results of the in vitro release test (Figure 4). This
initial burst of release could have slightly reduced cell pro-
liferation in comparison with the SrS and reference cements
(Figure 8).
However, in all cases, the daily doses of strontium
released per gram of cement (for example, for the 4.7% SrL
cement: 8 mg during the first day of the release test and
0.5 mg during the third week) were lower than the thera-
peutic doses used for oral administration and in the same
order of magnitude as the in situ dose proposed by Alkhrai-
sat (i.e., between 12 and 30 mg Sr/L).3,13 However, it is dif-
ficult to compare these two therapeutic routes (in situ or
oral administration) in terms of Sr level distribution locally
around the cement/bone defect and generally in circulating
blood.
Contrary to what was observed for the SrS cement, the
ratio of the Ca/Sr released rapidly stabilized at around 4.6
for the SrL cement, which exactly corresponded with the
initial Ca/Sr molar ratio (in the cement paste). This result
may indicate that the release mechanisms of SrS and SrL
cements are different. In order to investigate this point
further, the release kinetics shown in Figure 4(a,b) were
modeled. If release/dissolution kinetics fit the Higuchi
model, this indicates that diffusion is the main mechanism
involved in the release of the drug.47 The Higuchi model
links the percentage of the drug released, Q, to the time, t,
and k, a rate constant, as defined in the following equation:
Q ¼ k t1/2. Figure 12 shows that the evolution of Q as a
function of t1/2 for the release of strontium from the 8%
SrS and 4.7% SrL cements was linear for the SrS cement
and non-linear for the SrL cement. These results suggest
that for the SrS cement, strontium was released by diffusion
through the porous network created by the water inside the
cement, whereas such a mechanism was not involved or not
predominant for the SrL cement. In this latter case, the
release of strontium may have been limited by the dissolu-
tion of Sr-substituted apatite or its degradation when in the
presence of cells. This hypothesis was supported by Raman
micro-spectroscopy and EDX elemental mapping analyses
(Figures 6 and 7). Moreover, the results obtained with the
mercury porosimeter highlighted the creation of a second-
ary porous network for the SrS and SrL cements, which
could have been due to water diffusion into the cement.
Another parameter that could have been involved in the
higher release and dissolution rates of SrL cements during the
first week is related to the higher initial porosity of these
cements. According to the work of Cazalbou et al., the surface
of nanocrystalline biomimetic apatite which is formed during
cement setting can undergo fast Ca-Sr cationic exchanges
depending on the composition of the solution, which could
FIGURE 10. Relative mRNA expression levels of alkaline phosphatase
(ALP) and osteocalcin (OC) in human osteoprogenitor cells cultured
for 15 days on the three cements (Ref, SrL, and SrS cements) and on
plastic culture dishes as the control. Data of gene expression was
quantified relative to gene expression of the same cells cultured on
plastic dishes after the same time of culture.
FIGURE 11. Calcium (a) and strontium (b) concentrations in the
culture medium at different times before and during cell culture on
the three types of cement.
FIGURE 12. Representation of the release kinetics according to the
Higuchi model. Data shown are mean 6 SD (n ¼ 3).
have contributed to the initial burst of release of Sr that we
observed in vitro.1,48
Finally, another parameter involved in the release pro-
cess was the solubility of the apatite formed during the
cement setting reaction. The greater release of Sr and Ca
from the SrL cement is in agreement with the increase in
solubility with the increasing content of Sr2þ in the apatite
crystal.41,49 Interestingly, these results suggest that it is pos-
sible to control the release of Sr2þ and the biodegradation
of the cement by the method used to introduce strontium
into the cement paste.
Previous studies performed on Sr-loaded biomaterials
showed that the proliferation and differentiation of cells is
Sr-dose dependent.9,14,25 Therefore, a possible correlation
between the release/dissolution properties on the prolifera-
tion and differentiation of osteoprogenitor cells is discussed
in the next paragraph.
Effect of Sr-loaded cements on osteoblast cell activity
Several recent works investigated the effect of strontium
from Sr-doped mineral cements, coatings, and ceramics on
cell proliferation and differentiation.8–14,24,25,37
Alkhraisat et al. showed that cytocompatibility of Sr-con-
taining brushite cements was as good as that of reference
brushite cements (without Sr) via culturing the human
osteoblast cell line hFOB1.19.13 In addition, two cell lines
were tested on Sr-containing brushite cements by Pina
et al.: their results showed the stimulation of pre-osteoblas-
tic proliferation and osteoblastic maturation of MC3T3-E1
cells and non-cytotoxicity toward human osteosarcoma-
derived MG63 cells.8
In our study, regardless of the composition of cement
tested, the human bone marrow stromal cells showed simi-
lar proliferation profiles up to 9 days of culture. After this,
cell proliferation was 50% higher on the SrS cement com-
pared to reference and SrL cements (Figure 8). The correla-
tion between the results of cell proliferation (Figure 8) and
Sr release in vitro in the absence (Figure 4) and presence of
cells (Figure 11) suggested that the early released dose of
strontium had a determinant role on cell proliferation.
Braux and coworkers have recently determined the optimal
range of SrCl2 concentration in solution (between 10
$5 and
10$4 M) to enhance primary bone cell proliferation.9
This range of strontium concentrations is lower compared
with the strontium concentrations measured in the culture
medium during cell culture on the three types of cement
(Figure 11).
The promoter role of the three types of cement was con-
firmed by examining the high level of differentiation in gene
expression in comparison with the plastic culture dishes.
However, it appeared that strontium did not stimulate the
expression of the early bone marker (alkaline phosphatase),
or the late osteoblastic marker (osteocalcin). It is important
to note that titration of the Sr and Ca released in the cell
culture medium as a function of time revealed that the incu-
bation of Sr-loaded cements in IMDM medium for one night
before cell seeding avoided contact of the cells with the
highest doses of early released Sr (Figure 11).
These results show the beneficial effects of low doses of
strontium released (<8 mg/day/g of cement) on cell proli-
feration and differentiation that were closely related to the
sustained release of strontium from Sr-loaded vaterite-DCPD
cements.
In addition, we used human bone marrow stromal cells
that were driven to osteogenic differentiation by dexametha-
sone (inductive factor), and then cultured in IMDM medium.
The other papers published in the literature used different
cell lines including transformed cell lines cultured in basic
medium such as aMEM. The sensitivity of these differenti-
ated cells could be different depending on the length of
culture and the release of strontium within the medium in
contact with these Sr-loaded cements.
CONCLUSION
Strontium is a biocompatible and bioactive element that can
be introduced either as SrCO3 in the solid phase or as SrCl2#
6H2O dissolved in the liquid phase for the preparation of
original vaterite CaCO3-DCPD cement compositions. We
showed that the various cement compositions obtained led
to different release and dissolution behaviors, in agreement
with the solubility of the constituting phases of the set
cement (vaterite and apatite or strontium-substituted apa-
tites). The in vitro release test at 37!C and the cell culture
studies demonstrated that there was an initial burst of
release of strontium in the medium, (highest for the SrL
cement) followed by a sustained release over 3 weeks,
which did not have a deleterious effect on human osteopro-
genitor cell activity. The expression of an early bone marker
(alkaline phosphatase) and a later bone marker (osteocal-
cin), which levels were overexpressed after 15 days of cell
culture, was not significantly affected by the presence of
strontium either within the cements or released into the
medium. However, the enhanced proliferation of human
osteoprogenitor cells was observed after 15 days of culture
in contact with the SrS cement, which appeared to be the
most promising bioactive cement composition. Interestingly,
this study showed that the sustained release of Sr2þ, the
cement biodegradation rate and the biological activity could
be optimized by controlling the route of introduction of
strontium into the cement paste.
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